On Monday, Shares of Advaxis, Inc. (NASDAQ:ADXS), gained 7.87% to $17.81.
Advaxis, declared that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) awarded a grant totaling $1.1 million over three years to Baylor College of Medicine in support of an ongoing Phase 2 trial of Advaxis’s lead Lm Technology(TM) immunotherapy, axalimogene filolisbac (ADXS-HPV), in HPV-associated oropharynx (throat) cancer, a type of head and neck cancer.
The grant was administered through the FDA’s Orphan Products Grants Program, created more than 30 years ago by the Orphan Drug Act to promote the development of products for rare diseases. It is a competitive program that receives about 100 applications per year, from which typically 10 to 15 applications are selected for funding each fiscal year.
“Applications to the Orphan Products Grants Program undergo rigorous review for scientific and technical merit by a panel of experts to compete for funding,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “We are encouraged to see axalimogene filolisbac recognized as viable by being awarded a grant for its clinical research that could ultimately contribute to market approval.”
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor.
Shares of Ally Financial Inc (NYSE:ALLY), declined -0.10% to $20.85, during its last trading session.
Ally Corporate Finance, declared the formation of a team focused exclusively on fueling its expansion into the venture-backed technology sector.
The newly formed Ally Technology Finance group combines Ally Corporate Finance’s client-focused dedication and expertise in financing leveraged transactions with the experience and knowledge of industry veterans skilled in developing and executing transactions in the technology sector.
Ally Technology Finance will be led by Richard Suhl, who joins Ally Corporate Finance as senior managing director. Other members of this team comprise Christopher Erro, who joins Ally as senior director, Mike Griffin, who joins Ally as senior director, and Brian Baranaskas, a current director at Ally. The team is aligned under George Triebenbacher, the president of Ally Corporate Finance’s sponsor financing business.
Ally Financial Inc. provides financial products and services primarily to automotive dealers and their customers in the United States. It offers dealer financial services, counting a range of financial services and insurance products to automotive dealers and retail customers
At the end of Monday’s trade, Shares of Chimera Investment Corporation (NYSE:CIM), gained 1.30% to $14.01.
The Board of Directors of Chimera declared the declaration of its third quarter 2015 cash dividend of $0.48 per common share. This dividend is payable October 30, 2015, to common stockholders of record on September 30, 2015. The ex-dividend date is September 28, 2015.
The Board of Directors also declared that it anticipates to maintain a minimum quarterly dividend of $0.48 for the fourth quarter of 2015.
The Company distributes dividends based on its current estimate of taxable earnings per common share, not GAAP earnings. Taxable and GAAP earnings will typically differ due to items such as differences in premium amortization, accretion of discounts, unrealized and realized gains and losses, and credit loss recognition. Portions of the dividend may be ordinary income, capital gains or a return of capital.
Chimera Investment Corporation operates as a real estate investment trust in the United States. The company, through its auxiliaries, invests in residential mortgage-backed securities (RMBS), residential mortgage loans, commercial mortgage loans, real estate-related securities, and various other asset classes.
Finally, Travelers Companies Inc (NYSE:TRV), ended its last trade with -0.21% loss, and closed at $99.28.
Jay Fishman, Chairman and Chief Executive Officer of The Travelers Companies, planned to speak at the Barclays Global Financial Services Conference in New York City on Wednesday, Sept. 16, 2015, at 8:15 a.m. ET.
The Travelers Companies, Inc., through its auxiliaries, provides a range of commercial and personal property, and casualty insurance products and services to businesses, government units, associations, and individuals in the Unites states and internationally. It operates in three segments: Business and International Insurance; Bond & Specialty Insurance; and Personal Insurance.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
